Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · IEX Real-Time Price · USD
4.725
+0.615 (14.96%)
May 2, 2024, 10:00 AM EDT - Market open
Sagimet Biosciences Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Sagimet Biosciences stock have an average target of 39.6, with a low estimate of 26 and a high estimate of 67. The average target predicts an increase of 738.10% from the current stock price of 4.73.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SGMT stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $32 | Strong Buy | Initiates | $32 | +577.25% | May 2, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $37 → $27 | Strong Buy | Maintains | $37 → $27 | +471.43% | Mar 26, 2024 |
| Leerink Partners | Leerink Partners | Buy Initiates $26 | Buy | Initiates | $26 | +450.26% | Mar 25, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $47 → $46 | Buy | Maintains | $47 → $46 | +873.54% | Feb 7, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $30 → $37 | Strong Buy | Maintains | $30 → $37 | +683.07% | Jan 23, 2024 |
Financial Forecast
Revenue This Year
n/a
from 2.00M
Revenue Next Year
n/a
EPS This Year
-2.10
from -2.66
EPS Next Year
-3.77
from -2.10
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | n/a | 226.3M |
| Avg | n/a | n/a | n/a | n/a | 134.8M |
| Low | n/a | n/a | n/a | n/a | 47.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.61 | -2.75 | -4.68 | -3.27 | -2.36 |
| Avg | -2.10 | -3.77 | -4.93 | -3.17 | -2.30 |
| Low | -2.57 | -4.44 | -5.18 | -3.05 | -2.21 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.